Johnson & Johnson(JNJ) - Stock detail

Johnson & Johnson

US
JNJ
Johnson & Johnson(Listing date: 09/25/1944)

Johnson & Johnson was incorporated in New Jersey in 1887. Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacturing and sale of various products in the healthcare field. Johnson & Johnson is a holding company, with its operating companies located in nearly all countries around the world. The company's primary focus is on products related to human health and well-being. The company is divided into two business segments: Innovative Medicine and MedTech.

AI Rating

Rating methodology
Latest close (chg%)238.33-0.07%
Buy price
231.25
Target price245.00
Sell price229.00
P/E TTM27.29
P/E20.43
Confidence70%
Risk score60/100
AI Summary
The committee acknowledges JNJ's fundamental transformation and positive long-term growth prospects but identifies significant short-term risks from overbought technical indicators (RSI_6 at 76.58, KDJ J-value at 102.22). The current price offers limited upside (~2.8%) to target while facing high probability of consolidation/pullback. Persistent talc litigation creates headline risk. The optimal strategy is to hold existing positions while waiting for a better risk-reward entry point.

Alpha Score

0-10
  • Trend（Score 0/10）

    No summary available

  • Valuation（Score 5/10）

    The stock appears fairly valued with a current price of $238.33 falling within the middle of the calculated fair value range of $230-$250. Forward P/E of 20.43 is reasonable for a large-cap healthcare company, while elevated TTM P/E and P/B ratios reflect the company's intangible assets and post-spin-off segment mix.

  • Financial strength（Score 6/10）
    Financial condition shows generally stable health with sufficient liquidity, moderate leverage typical for the industry, and strong cash flows, though extremely high net margins in recent quarters require careful interpretation due to potential one-time events.
  • Profitability（Score 7/10）
    Profitability metrics show strong underlying operational performance with consistently robust gross margins and solid return metrics, though recent extraordinary net profit growth figures are likely driven by non-recurring items.
  • Sentiment（Score 7/10）
    Johnson & Johnson presents a mixed but overall positive outlook with strong clinical pipeline successes in rare diseases and oncology offset by persistent talc litigation risks, reinforcing its long-term value as a defensive dividend growth stock.
Latest price
$238.33-0.07%
Market cap573.71B
P/E TTM27.29
P/E20.43
Volume7.39M
Turnover1.77B